【Cheng Yeh Medical】Company announces that its important subsidiary, Xing Ye Biotechnology Co., Ltd., has signed a syndicated loan agreement with a banking consortium
Key facts
- 【Cheng Yeh Medical】Company announces that its important subsidiary, Xing Ye Biotechnology Co., Ltd., has signed a syndicated loan agreement with a banking consortium
- Cheng Yeh Medical's important subsidiary, Xing Ye Biotechnology Co., Ltd., has signed a syndicated loan agreement for NT$5.3 billion with a consortium of banks, including First Commercial Bank. This agreement aims to replenish working capital and is valid for seven years from the first drawdown date.
- Source: PR Times
- Date: May 8, 2026
Direct answer
Cheng Yeh Medical's important subsidiary, Xing Ye Biotechnology Co., Ltd., has signed a syndicated loan agreement for NT$5.3 billion with a consortium of banks, including First Commercial Bank. This agreement aims to replenish working capital and is valid for seven years from the first drawdown date.
- Citation
- 【Cheng Yeh Medical】Company announces that its important subsidiary, Xing Ye Biotechnology Co., Ltd., has signed a syndicated loan agreement with a banking consortium (May 8, 2026), PR Times
- Source
- PR Times
- Date
- May 8, 2026
Cheng Yeh Medical's important subsidiary, Xing Ye Biotechnology Co., Ltd., has signed a syndicated loan agreement for NT$5.3 billion with a consortium of banks, including First Commercial Bank. This agreement aims to replenish working capital and is valid for seven years from the first drawdown date.
📋 Article Processing Timeline
- 📰 Published: May 8, 2026 at 09:00
- 🔍 Collected: May 9, 2026 at 08:00 (23h 0m after Published)
- 🤖 AI Analyzed: May 9, 2026 at 09:19 (1h 19m after Collected)
2. Counterparty to the contract or commitment: First Commercial Bank, Taipei Fubon Commercial Bank, and other 6 syndicated loan banking consortiums.
3. Relationship with the company: None
4. Start and end dates of the contract or commitment (or termination date): 7 years from the first drawdown date.
5. Main content (not applicable to termination): Syndicated loan agreement for NT$5.3 billion.
6. Restrictive clauses (not applicable to termination): Handled in accordance with the syndicated loan agreement.
7. Commitments (not applicable to termination): Handled in accordance with the syndicated loan agreement.
8. Other important agreed matters (not applicable to termination): Handled in accordance with the syndicated loan agreement.
9. Impact on the company's finance and business: Replenishment of working capital
10. Specific purpose: Replenishment of working capital
11. Other matters that need to be specified (If the subject of the event or resolution is a public company or above, this material information also meets the requirements of Article 7, Paragraph 8 of the Enforcement Rules of the Securities and Exchange Act regarding matters that have a significant impact on shareholders' equity or securities prices): None
Keyword: Material Information
FAQ
What are the key facts in this article?
Cheng Yeh Medical's important subsidiary, Xing Ye Biotechnology Co., Ltd., has signed a syndicated loan agreement for NT$5.3 billion with a consortium of banks, including First Commercial Bank. This agreement aims to replenish working capital and is valid for seven years from the first drawdown date.
What is the direct answer?
Cheng Yeh Medical's important subsidiary, Xing Ye Biotechnology Co., Ltd., has signed a syndicated loan agreement for NT$5.3 billion with a consortium of banks, including First Commercial Bank. This agreement aims to replenish working capital and is valid for seven years from the first drawdown date.
What is the source and date?
PR Times: https://mops.twse.com.tw/material/twse-4164-2026-05-08-d4d56e3c | May 8, 2026